SPINK1 and pancreatitis risk: mechanisms, clinical impact and management
SPINK1 encodes the pancreas's first-line trypsin inhibitor. Loss of its function lowers the threshold for trypsin-driven injury. This review summarises what is known about its variants, how much they change disease risk, and what the evidence says about managing the consequences.
Updated Sept 2026— references, each checked against PubMedAudience patients, families, cliniciansStatus educational, not medical advice
Key points
SPINK1 is a modifier gene, not a verdict. The common N34S haplotype raises the odds of chronic pancreatitis (CP) about 11-fold, but most carriers never develop disease.
N34S itself is functionally neutral. The causal element on its haplotype is the enhancer variant c.-4141G>T, which lowers SPINK1 transcription.
Variant class matters. Complete loss-of-function variants act dominantly with about 55% penetrance. The East Asian c.194+2T>C variant is a severe partial loss of function.
Risk is multiplicative. Co-inherited CFTR, CTRC or PRSS1 variants, smoking, heavy alcohol and hypertriglyceridaemia add to SPINK1-related risk.
Management follows the disease stage, not the genotype. No SPINK1-targeted therapy exists in humans. AAV gene therapy protects mice, and camostat failed a phase 2 trial.
~2%
N34S carriers among people of European ancestry
11.0OR
Pooled odds of CP in N34S carriers (95% CI 7.6–15.9)
≈99%est.
Share of single-copy N34S carriers estimated never to develop CP (see Fig. 4)
25.7OR
Pooled odds of CP for c.194+2T>C (73.2 in East Asians)
1
Gene and protein
Scroll through the story below. It zooms from the organ down to the molecule, then shows how the main variants break the chain. The full interactive map follows in Figure 1.
Story 1From organ to moleculeschematic · not to scale
01 · The organ
A gland that could digest itself
The pancreas makes digestive enzymes strong enough to break down the organ itself. To stay safe, it makes them as inactive precursors that switch on only in the gut.
ELI5 · in plain wordsYour pancreas makes juices that break down food. They are so strong they could break down the pancreas itself, so it makes them switched off, and they only switch on once they reach your gut.
02 · The cell
Inside an acinar cell
Acinar cells store trypsinogen, the precursor of trypsin, in zymogen granules. Trypsin-inhibiting activity sits in those same granules, so the brake travels with the enzyme.
ELI5 · in plain wordsThink of each cell as a small factory. It packs food-cutting scissors (trypsinogen) into boxes, and puts safety covers (SPINK1) in the same boxes in case a pair of scissors opens too early.
03 · The chromosome
Chromosome 5, band q32
The instructions for that inhibitor, SPINK1 (also called PSTI or TATI), sit on the long arm of chromosome 5. It was first isolated from the pancreas in 1948.
ELI5 · in plain wordsEvery cell carries a giant instruction book split into 23 pairs of volumes, called chromosomes. The instructions for the safety cover are in volume 5, at a spot called 5q32.
04 · The gene
Four exons, about 7.5 kb
The pancreatic form of the gene has four protein-coding exons separated by non-coding introns.
ELI5 · in plain wordsThe recipe for SPINK1 is written in four useful chunks (exons), with stretches of filler (introns) in between that the cell will throw away.
05 · Gene to protein
Splice, translate, trim
The introns are spliced out and the joined exons are translated into a 79-residue precursor. Its 23-residue signal peptide is cut off during secretion, leaving the 56-residue inhibitor.
ELI5 · in plain wordsThe cell cuts out the filler and glues the four useful chunks into one clean copy of the recipe, then builds the protein from it. The new protein has a shipping label on its front (the signal peptide) that tells the cell to send it out. The label is torn off on the way out, and what is left is the working safety cover.
06 · Mechanism
Lock and key
The mature protein folds into a Kazal domain. Its reactive-site loop, around Lys41–Ile42, fits into trypsin's active site and blocks it.
ELI5 · in plain wordsTrypsin works like a pair of scissors. SPINK1 has a part shaped just like the thing the scissors want to cut, so it slots between the blades and jams them shut.
07 · Variant: N34S
The famous passenger
N34S changes one amino acid in exon 3, but the protein is secreted and works normally. The damage comes from c.-4141G>T, about 4 kb upstream. It weakens an enhancer and lowers SPINK1 production, and the two are inherited together.
ELI5 · in plain wordsN34S is a spelling change in the recipe that is harmless on its own. But it is almost always inherited together with another change further back in the book, and that change turns down the volume on the recipe, so the cell makes less SPINK1. N34S is just the easy-to-spot sign that the real culprit is nearby.
08 · Variant: c.194+2T>C
Exon 3 goes missing
One base change at the start of intron 3 breaks the splice signal, so exon 3, which encodes the trypsin-binding region, is skipped. About 10% of normal message remains. It is the most common SPINK1 variant in East Asian patients.
ELI5 · in plain wordsThis change smudges the “cut here” mark next to chunk 3. The cell cuts in the wrong place and drops chunk 3, which holds the part that jams the scissors. Most copies come out broken; only a few come out right.
09 · Variant: L14P / L14R
Made, but stuck
Signal-peptide variants stop SPINK1 from being secreted. The protein is degraded inside the cell, so the granules lose their brake. These variants cause dominant hereditary pancreatitis.
ELI5 · in plain wordsHere the shipping label is misprinted. The cell makes SPINK1 but cannot send it out, so it throws it away, and the boxes of scissors end up without their safety cover.
10 · Explore
Now explore every variant
Figure 1 below maps all the main variants on the gene and protein. Click any of them for its mechanism, frequency and evidence.
ELI5 · in plain wordsBelow is a map of the recipe. Click any spelling change to see what it does.
Complete / severe loss of functionPartial loss of functionNon-functional passenger / likely benign
Figure 1 | SPINK1 locus (top) and protein (bottom). Select a variant to see its mechanism, frequency and evidence. The schematic is not to scale: introns are compressed and exon widths reflect coding length. Protein numbering is precursor numbering. The reactive-site bond Lys41–Ile42 is where SPINK1 docks into trypsin's active site.
2
Physiological role: the first layer of defence
Scroll to watch a live, agent-based model of one acinar cell. Each defence layer switches on in turn, then the cell gets one hit, then two. At the end the controls unlock so you can try it yourself. The waterfall in Figure 2 follows the same parameters.
Story 2Inside an acinar cell · live model
L1 · SPINK1L2 · CTRCL3 · flushing+ trigger
free trypsin in cell 0
trypsinogenactive trypsinSPINK1 / bounddegraded by CTRCflushed out
01 · Resting cell
Inactive enzymes flow out
Trypsinogen (grey) leaves the granules and drifts towards the duct, still inactive. SPINK1 (blue) travels with it.
The bar under the model shows what happens to activated trypsin over the last ~10 seconds.
ELI5 · in plain wordsThe factory is quiet. Switched-off scissors (grey dots) flow out through a pipe towards the gut, with safety covers (blue dots) mixed in.
02 · The problem
Some switch on too early
A small fraction of trypsinogen activates inside the cell. With the defences switched off, active trypsin (orange) roams freely and activates more trypsinogen, starting a chain reaction.
Defences are off only for this demonstration.
ELI5 · in plain wordsNow and then a pair of scissors opens too early (orange). If nothing stops it, it opens other scissors, which open more, like falling dominoes. The safety systems are switched off here to show what that looks like.
03 · Layer 1
SPINK1 binds on contact
SPINK1 stored with the zymogens binds active trypsin straight away, forming inert complexes (blue rings). Its capacity is limited, to about 13% of potential trypsin activity by one estimate. On its own it cannot catch everything.
ELI5 · in plain wordsThe safety covers grab open scissors as soon as they bump into them and jam them shut (blue rings). There are only so many covers, though, so a few scissors still get past.
04 · Layer 2
CTRC destroys escapees
Chymotrypsin C degrades trypsin that slips past SPINK1 (violet fragments). Variants that weaken CTRC are themselves risk factors for CP.
ELI5 · in plain wordsA second guard, CTRC, chops up any open scissors that slipped past the covers (purple bits).
05 · Layer 3
Flushing through the duct
CFTR-driven fluid secretion washes zymogens and any leftover trypsin into the duct. With all three layers working, the cell stays calm. This is the reference state.
ELI5 · in plain wordsFinally, a steady stream of fluid flushes everything down the pipe and out of the cell. With all three safety systems working, the cell stays calm.
06 · One hit
A SPINK1 variant halves the brake
With SPINK1 at 50%, as in a complete loss-of-function heterozygote, more trypsin slips past layer 1. CTRC and flushing still mostly cope. In mice, heterozygous Spink1 deficiency worsened pancreatitis and promoted CP after an acute episode.
ELI5 · in plain wordsNow the cell has only half its usual safety covers, as if one copy of the SPINK1 recipe were broken. More scissors slip past, but the other two guards still mostly keep up.
07 · Two hits
Add a trigger and the defences fail
Now raise the activation rate, as heavy alcohol or another insult might. Escaped trypsin activates more trypsinogen, and the chain reaction outruns layers 2 and 3. This is the multiple-hit model of pancreatitis risk.
ELI5 · in plain wordsAdd a second problem, such as heavy drinking, so that many more scissors open at once. There are now too many for the guards, the dominoes start falling and the cell gets hurt. It usually takes more than one problem at the same time.
08 · Your turn
Try it yourself
The controls under the model are now unlocked. Lower CFTR flushing to mimic a co-inherited CFTR variant, or restore SPINK1 and watch the cell recover. Figure 2 below updates to match.
Schematic model: particle counts, rates and thresholds are illustrative, not measured, and this is not a personal risk estimate.
ELI5 · in plain wordsYour turn: use the sliders to break or fix each safety system and watch what happens to the cell.
Figure 2 | Conceptual "multiple-hit" model of intrapancreatic trypsin control. Bars show prematurely activated trypsin and how much is left after each defence layer. The dashed lines mark illustrative stress and injury thresholds. Parameters are illustrative, not measured, and this is not a personal risk calculator. The preset SPINK1 levels are rough: c.194+2T>C keeps about 10% normal transcript from the variant allele; complete-LoF heterozygotes keep one working allele; the size of the N34S-haplotype reduction is not well quantified.
3
Variant spectrum
SPINK1 variants range from functionally neutral to complete loss of function. A 2025 synthesis puts them on this continuum. Complete-LoF alleles cause dominant disease with incomplete penetrance, while hypomorphic alleles such as c.194+2T>C and the N34S haplotype act as risk factors. Click a row to highlight it in Figure 1.
Variant
Class
Mechanism
Where found
Effect size
Refs
Zygosity
Biallelic c.194+2T>C gives OR ~162 (vs ~30 for heterozygotes) and onset about 10 years earlier. For N34S, severity and age at onset did not clearly differ between homozygotes and heterozygotes. Two complete-LoF alleles can cause severe isolated exocrine insufficiency in infancy.
Gene–gene interaction
Trans-heterozygosity (variants in two different CP genes) gave OR 38.7. SPINK1 plus CFTR p.R75Q gave OR 25.1. An early report of ~900-fold risk for CFTR + N34S rested on 39 patients.
4
Disease risk: relative and absolute
Odds ratios describe how much a variant multiplies risk. They do not say how likely disease is for an individual. CP is uncommon, with a population prevalence of roughly 42–92 per 100,000. So even a large relative increase leaves most carriers unaffected.
Figure 3Forest plot of published effect estimates
Figure 4Absolute scale: 1,000 people
Figure 4 | Illustrative absolute risk of chronic pancreatitis. The general-population figure uses CP prevalence of 0.04–0.09%. The carrier figure multiplies that range by the pooled OR of 11.0. For a rare outcome the OR approximates the relative risk. This is an estimate, not a measured lifetime risk; no cohort has measured it directly. It does not apply to complete-LoF variants, which carry far higher risk.
5
Clinical course and complications
In a French cohort of 209 patients with SPINK1-related pancreatitis, median age at onset was 20.1 years, against 41.2 for idiopathic disease. In children, SPINK1 variants were over-represented in CP compared with recurrent acute pancreatitis.
Figure 5Disease continuum (select a stage)
Figure 5 | The pancreatitis continuum. Progression is not inevitable. Most N34S carriers stay at stage 1, and each later transition can be slowed by removing modifiable risk factors.
Figure 6Reported frequency of complications
Figure 6 | Complication frequencies from different study populations. The bars are not directly comparable: bone data are from an adult CP meta-analysis, EPI and diabetes from the pediatric INSPPIRE-2 cohort, and invasive intervention from a population-based adult CP cohort. Hover for details.
Cancer risk
Long-standing CP of any cause raises pancreatic cancer risk. The relative risk is 16.2 within 2 years of diagnosis, partly because some cancers present as pancreatitis, and falls to 3.5 after 9 or more years. SPINK1 on its own was not associated with cancer in a meta-analysis, a Chinese CP cohort or a 4,528-case germline study. A French cohort did report higher risk within SPINK1-related pancreatitis.
Quality of life
Physical and mental component scores are substantially below those of controls. Constant pain, disability or unemployment, and current smoking determine quality of life. The cause of pancreatitis does not. Recurrent acute pancreatitis lowers quality of life even without established CP.
6
Management: what the evidence supports
Management depends on the disease stage rather than the genotype. The tables grade each intervention by its strongest supporting evidence.
Meta-analysisRCTGuidelineObservationalPreclinical
Intervention
Evidence
Key finding
Refs
7
Care pathway tool
Answer two questions to see a summary of steps drawn from the guidelines cited in Section 6. It supports a conversation with your clinician and does not replace one.
1 · Pancreatitis history
2 · Variant class on the report
8
Inheritance
SPINK1 alleles segregate in a Mendelian way. Whether disease appears depends on the variant class and on other genetic and environmental factors. Choose each parent's genotype to see the expected distribution among their children.
Parent A
Parent B
variant allele typical allele
Figure 8 | Punnett square for one SPINK1 variant. Each pregnancy is independent. "Carrier" describes the genotype, not a disease: for N34S most heterozygotes stay unaffected, while complete-LoF heterozygotes have about 55% penetrance. Testing of children is usually part of a pancreatitis workup, not screening.
9
Research landscape
Figure 9Timeline of key findings (select a point)
Figure 9 | Eight decades of SPINK1 research. The axis is compressed before 1995.
Figure 10Therapeutic pipeline relevant to SPINK1-related pancreatitis
Figure 10 | Development stage and outcome.AAV8-hSPINK1 protected mice in three models, mostly when given before disease onset. Its vector design is being refined, and Spink1 promoted survival of Kras-mutant acinar cells in mice.Camostat showed no benefit over placebo in the 264-patient TACTIC trial.CFTR modulators reduced attacks in pancreas-sufficient CF but may increase them in pancreas-insufficient CF.Nafamostat reduces post-ERCP pancreatitis. ClinicalTrials.gov listed no SPINK1-targeted interventional trial as of Sept 2026.
10
Questions for your clinician
Tick the questions you want to raise. Your selections are saved in this browser and included when you print.
Educational resource, not medical advice. Figures come from the cited studies and vary with population and study design. Decisions about genetic testing, diet, medication or procedures should be made with a gastroenterologist or pancreatologist and a genetic counsellor who know your full history.
R
References
sources. Journal articles were checked against their PubMed records (authors, title, journal, year, PMID). The 1948 paper predates PubMed and is linked by DOI. This is a curated set of landmark and directly relevant studies, not a complete bibliography; for the full literature, search PubMed.